期刊簡介 | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | PHARMACOGENOMICS JOURNAL LetPub Score 6.3
50 ratings
Rate
Reputation 7.6 Influence 5.1 Speed 7.0 | ||||||||||||||||||||||||
期刊簡稱 | PHARMACOGENOMICS J | ||||||||||||||||||||||||
ISSN | 1470-269X | ||||||||||||||||||||||||
E-ISSN | 1473-1150 | ||||||||||||||||||||||||
h-index | 78 | ||||||||||||||||||||||||
CiteScore |
| ||||||||||||||||||||||||
自引率 (2023-2024) | 0.00%自引率趨勢 | ||||||||||||||||||||||||
掲載範囲 |
| ||||||||||||||||||||||||
官方網站 | https://www.nature.com/tpj | ||||||||||||||||||||||||
在線稿件提交 | https://mts-tpj.nature.com/ | ||||||||||||||||||||||||
開放訪問 | No | ||||||||||||||||||||||||
出版商 | Springer Nature | ||||||||||||||||||||||||
主題領域 | 医学 | ||||||||||||||||||||||||
出版國/地區 | UNITED STATES | ||||||||||||||||||||||||
發行頻率 | 四半期刊行 | ||||||||||||||||||||||||
創刊年 | 2001 | ||||||||||||||||||||||||
每年文章數 | 21每年文章數趨勢 | ||||||||||||||||||||||||
黃金OA百分比 | 29.73% | ||||||||||||||||||||||||
Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q2
| ||||||||||||||||||||||||
索引 (SCI or SCIE) | Science Citation Index Expanded | ||||||||||||||||||||||||
鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1470-269X%5BISSN%5D | ||||||||||||||||||||||||
平均審稿時間 * | 來自出版商的數據: 來自作者的數據: Slow, 6-12 Week(s) | ||||||||||||||||||||||||
競爭力 * | 來自作者的數據: Ordinary | ||||||||||||||||||||||||
參考鏈接 |
| ||||||||||||||||||||||||
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 |
|
|
首頁 上一頁 1 下一頁 末頁 (頁 | |
[PHARMACOGENOMICS JOURNAL] 的評論 | 撰寫評論 |
作者: 奉天俊强 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-02-07 13:49:53 評論於 Has been demoted to Zone 3(0) 讚! | 奉天俊强 |
作者: 水月戊寅 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2019-12-09 11:03:18 評論於 Review Speed: 10.0 Sharing Experience: This journal is extremely slow, the article was under review for nearly eight months before being sent for review, and only sent to one reviewer in the end. After revising, it was rejected, stating that the concept of the article was not new. Originally, it was just a small review, but being delayed for so long, even new concepts become old. This journal is a pit, hoping to help everyone avoid it. Of course, if you have plenty of time and don't mind at all, you can also try your luck(0) 讚! | 水月戊寅 |
作者: Jane07 領域: 医学 審稿時間: 10.0 month(s) 結果: 拒稿 撰寫評論 |
2019-12-09 09:21:10 評論於 This journal was super dilatory. The article was kept for nearly eight months before being sent for review. In the end, it was sent to only one reviewer. After being revised, it was rejected, saying that the concepts of the article were not new. I intended to write a mini review. No matter how new the concepts were, they became old after being delayed for so long. I hope to help you avoid the incomprehensible journal. Of course, if you have a lot of time and don’t care at all, you can still have a try. (0) 讚! | Jane07 |
作者: 是你的沛海呀 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2019-07-31 10:08:38 評論於 Could you please tell me if there have been any changes in the status? Or does "under consideration" mean the same as "under review"? Thank you(0) 讚! | 是你的沛海呀 |
作者: 飞松mio 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2019-05-19 22:36:12 評論於 I am planning to invest in pharmacogenomics. Will it be very popular?(0) 讚! | 飞松mio |
作者: 玉女志敏 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2019-04-23 19:24:23 評論於 Review speed: 6.0 | Submission success rate: 50.0 Experience sharing: Submitted on 2018-11-02, under consideration on 11-20, and status has not changed since then... The editorial office even sent an apology letter on 03-27... Cute(0) 讚! | 玉女志敏 |
作者: 魔都锦玉 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2017-01-19 16:13:39 評論於 Submitted a meta-analysis for review over a month ago, but it was rejected(0) 讚! | 魔都锦玉 |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2011-06-29 21:09:43 評論於 Focused research direction: Genomics(0) 讚! | 凌霄高洁 |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2011-02-26 22:09:15 評論於 It's not easy(0) 讚! | 凌霄高洁 |
首頁 上一頁 1 下一頁 末頁 (頁 |
Contact us